Our focus

We are focused on developing and providing treatment options that address a range of unmet medical needs in chronic respiratory diseases such as in asthma, COPD, and cystic fibrosis. In the area of inhaler therapies we are committed to addressing sub-optimal disease control caused by patients’ poor inhaler technique and poor adherence with inhalers. We are at the forefront of developing innovative solutions that may reduce the disease burden on patients and health care providers.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Our family of respiratory products treats a variety of respiratory conditions ranging from asthma, severe eosinophilic asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.